Tim Lugo
Stock Analyst at William Blair
(0.45)
# 3,989
Out of 4,862 analysts
25
Total ratings
33.33%
Success rate
-28.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Lugo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EYEN Eyenovia | Downgrades: Market Perform | n/a | $2.44 | - | 2 | Nov 15, 2024 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | n/a | $56.22 | - | 3 | Oct 30, 2024 | |
| APLT Applied Therapeutics | Initiates: Outperform | n/a | $0.35 | - | 1 | Jul 31, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | n/a | $29.00 | - | 1 | Apr 15, 2024 | |
| SLDB Solid Biosciences | Initiates: Outperform | $40 | $4.51 | +786.92% | 1 | Mar 28, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Outperform | n/a | $9.13 | - | 1 | Mar 12, 2024 | |
| ABBV AbbVie | Upgrades: Outperform | n/a | $191.08 | - | 2 | Jan 29, 2024 | |
| ACRS Aclaris Therapeutics | Downgrades: Market Perform | n/a | $1.47 | - | 1 | Nov 13, 2023 | |
| TVTX Travere Therapeutics | Downgrades: Market Perform | n/a | $14.50 | - | 1 | Sep 21, 2023 | |
| SPRY ARS Pharmaceuticals | Downgrades: Market Perform | n/a | $15.39 | - | 2 | Sep 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.21 | - | 3 | Jul 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $62 | $6.70 | +825.37% | 1 | Jun 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.16 | - | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $32.74 | - | 1 | Jan 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.15 | - | 2 | Sep 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.28 | - | 1 | May 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $46 | $15.46 | +197.54% | 1 | May 30, 2017 |
Eyenovia
Nov 15, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.44
Upside: -
BioMarin Pharmaceutical
Oct 30, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $56.22
Upside: -
Applied Therapeutics
Jul 31, 2024
Initiates: Outperform
Price Target: n/a
Current: $0.35
Upside: -
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $29.00
Upside: -
Solid Biosciences
Mar 28, 2024
Initiates: Outperform
Price Target: $40
Current: $4.51
Upside: +786.92%
Zevra Therapeutics
Mar 12, 2024
Initiates: Outperform
Price Target: n/a
Current: $9.13
Upside: -
AbbVie
Jan 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $191.08
Upside: -
Aclaris Therapeutics
Nov 13, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.47
Upside: -
Travere Therapeutics
Sep 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $14.50
Upside: -
ARS Pharmaceuticals
Sep 20, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $15.39
Upside: -
Jul 22, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.21
Upside: -
Jun 16, 2021
Downgrades: Market Perform
Price Target: $62
Current: $6.70
Upside: +825.37%
Nov 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.16
Upside: -
Jan 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $32.74
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.15
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.28
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: $46
Current: $15.46
Upside: +197.54%